Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) | RFA CA 21 007

Opportunity Information: Apply for RFA CA 21 007

This NIH/National Cancer Institute funding opportunity (RFA-CA-21-007) supports revision applications to active NCI-funded R01 projects, with the goal of speeding up or expanding the parent study by adding a new technology that was developed with NCI Innovative Molecular Analysis Technologies (IMAT) program support. In practice, it is designed for research teams who already have an ongoing R01 and want to incorporate an IMAT-supported instrument, platform, or technical approach to either broaden the original aims or accelerate the pace and impact of the existing work. A key idea behind the announcement is that promising IMAT technologies often need rigorous, independent validation in real-world research settings before they are widely adopted, and these revision awards are meant to help bridge that gap by placing emerging tools into appropriate cancer research communities.

The main scientific purpose is twofold: first, to incentivize independent testing and validation of novel IMAT-supported technologies within the context of a currently funded cancer research project; and second, to promote faster adoption of those technologies by demonstrating their value for answering important cancer biology, prevention, diagnosis, treatment, or related research questions. The FOA emphasizes that the revision should clearly build on the parent grant by either expanding the scope of the original research questions or materially accelerating progress toward the original objectives. The technology component is not meant to be a generic methods upgrade; it is specifically tied to incorporating a technical approach or instrument that originated from NCI IMAT funding, aligning the revision with IMATs broader mission of enabling innovative molecular and analytical methods for cancer research.

The award mechanism is an R01 revision (formerly known as a competing revision), meaning applicants are not proposing a brand-new standalone project. Instead, they submit a request to modify and add to an existing R01 in a way that remains anchored to the funded parent award. The announcement is labeled "Clinical Trial Optional," which signals that applicants may propose a clinical trial component if it is appropriate and justified for the revision, but a clinical trial is not required. The overall activity category is listed under Education and Health, and the program is associated with CFDA number 93.394.

Funding details in the provided source indicate an award ceiling of $150,000. The expected number of awards is not specified in the excerpt. The original closing date listed is 2021-09-29, and the FOA record creation date is 2020-11-24, indicating this was a time-bound opportunity tied to a specific receipt window.

Eligibility is broad and includes many typical NIH-eligible applicant organizations, spanning public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district), as well as independent school districts and public housing authorities/Indian housing authorities. It also includes federally recognized Native American tribal governments and Native American tribal organizations that are not federally recognized tribal governments. The FOA also explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities/foreign organizations. This breadth reflects an intent to encourage participation from a wide range of research settings and communities, including institutions that serve historically underrepresented populations and organizations outside the United States when appropriate.

At its core, the opportunity is about accelerating cancer research by pairing active, question-driven R01 projects with cutting-edge IMAT-derived technologies in a way that produces clear, publishable evidence that the new technology improves capability, speed, rigor, or reach. Successful revision applications under this FOA would be expected to make a strong case that the added IMAT-supported approach is both technically and scientifically compelling for the parent projects goals, and that the revision work will meaningfully advance cancer research by validating and demonstrating the technologys utility in an independent, mission-relevant context.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on 2020-11-24.
• Applicants must submit their applications by 2021-09-29. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $150,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 21 007

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: